-+ 0.00%
-+ 0.00%
-+ 0.00%

UK Regulator OKs Eli Lilly's Once-weekly Onswik for Type 2 Diabetes

MT Newswires·10/13/2026 10:24:17
Listen to the news
10:24 AM EDT, 10/13/2026 (MT Newswires) -- The UK's Medicines and Healthcare products Regulatory Agency approved Eli Lilly's (LLY.SW, LLY.F) Onswik, or insulin efsitora alfa, for adults with type 2 diabetes mellitus. The medicine company's once-weekly, long-acting basal insulin could cut the number of injections needed for type 2 diabetes to 52 a year from up to 365, according to a Tuesday notice. The approval followed a "rigorous" assessment of the available evidence. The regulator said it will keep monitoring the medicine's safety closely through its established surveillance systems.